Breath test device and method
View Patent ↗The disclosure relates to breath test devices and methods for the evaluation of liver functional and metabolic capacity or to assess liver heath and/or degree of liver injury. Specifically, there is provided a method of evaluating a liver condition, the method includes on-line monitoring a metabolic product of methacetin, a salt or a derivative of methacetin, in a subject's breath after administering to the subject isotope labeled methacetin, a salt or a derivative thereof in water solution form. There is also provided a device for evaluating a liver condition, the device includes one or more sensors adapted to monitor on-line an isotope level of a metabolic product of labeled methacetin, or a salt or a derivative of methacetin in a subject's breath and a controller adapted to sample measurements of the one or more sensors at a continuous mode.
1. A method of quantitatively evaluating a liver function and/or a degree of liver injury in a subject, the method comprising:
providing solution samples of isotope-labeled methacetin or a salt or a derivative thereof wherein the solution samples are produced in a process comprising:
mixing, in a pre-determined amount of water, a pre-determined amount of isotope-labeled methacetin or the salt or the derivative thereof, to produce a solution;
analyzing the solution to measure an amount of the methacetin or the salt or the derivative thereof dissolved in the solution; and
providing for administration solution samples wherein, according to the analysis of the solution, at least 90% of the pre-determined amount of methacetin, or the salt or the derivative thereof, is dissolved in the solution;
administering the analyzed solution sample to a subject in need thereof;
following the administering, measuring a change in isotope ratio of a metabolic product of the isotope-labeled methacetin, or the salt or the derivative thereof, in the subject's breath using a breath sensor adapted to monitor the metabolic product of the isotope-labeled methacetin or the salt or the derivative thereof; and
quantitatively evaluating the liver function and/or the degree of liver injury based on the measured change in the isotope ratio.
2. The method of claim 1 , wherein the at least 90% of the pre-determined amount of methacetin, or the salt or the derivative thereof comprises over 99% of the pre-determined amount of isotope-labeled methacetin, the salt or the derivative thereof.
3. The method of claim 1 , wherein administration comprises oral, intravenous, an implemented device, or any combination thereof.
4. The method of claim 1 , wherein the isotope-labeled methacetin, or the salt or the derivative thereof comprises methacetin or salt or derivative thereof labeled with carbon-13, carbon-14, oxygen-18 or any combination thereof.
5. The method of claim 1 , further comprising administering to the subject a test meal.
6. The method of claim 1 , further comprising:
on-line monitoring a metabolic product of the isotope-labeled methacetin, the salt or the derivative thereof, in the subject's breath after administering the analyzed solution to the subject.
7. The method of claim 6 , further comprising monitoring CO 2 in breath.
8. The method of claim 7 , further comprising analyzing at least one breath related parameter obtained by measuring the change in the isotope ratio of the metabolic product of the isotope-labeled methacetin, the salt or the derivative thereof, in combination with at least one breath related parameter obtained by monitoring CO 2 in breath.
9. The method of claim 8 , further comprising analyzing at least one breath related parameter obtained by measuring the change in the isotope ratio of the metabolic product of the isotope-labeled methacetin, the salt or the derivative thereof, in combination with at least one physiological and/or medical parameter.
10. The method of claim 9 , wherein the physiological and/or medical parameter comprises age, gender, weight, height, blood related parameter, body mass index (BMI), waist circumference, medication therapy related parameter or any combination thereof.
11. The method of claim 6 , further comprising a follow-up of the liver function and/or the degree of liver injury, wherein the method further comprises:
repeating, after a predetermined period of time, the step of on-line monitoring a metabolic product of the isotope-labeled methacetin, the salt or the derivative thereof, in a subject's breath after administering the analyzed solution to said subject.
12. The method of claim 11 , wherein the predetermined period of time comprises between 0.5 minutes and 4 hours.
13. The method of claim 11 , wherein the predetermined period of time comprises between 4 hours and 12 months.
14. The method of claim 6 , wherein the subject exhibits a normal enzymatic activity.
15. The method of claim 1 , wherein the evaluation of the liver function and/or degree of injury of the liver comprises distinguishing between levels of fibrosis.
16. The method of claim 15 , wherein the levels of fibrosis comprise a level 0, a level 1 and a level 2, which correlate to the subject's levels of liver disease according to a standard fibrosis score.
17. The method of claim 16 , wherein the fibrosis is related to a liver disease.
18. The method of claim 1 , further comprising administering to the subject a liver challenging test meal.
19. The method of claim 1 , wherein:
mixing, in the pre-determined amount of water, the pre-determined amount of isotope-labeled methacetin or the salt or the derivative thereof comprises stirring the isotope-labeled methacetin, the salt or the derivative thereof in the pre-determined water at a temperature in the range of 20° C.-100° C., and
measuring the change in isotope ratio in the subject's breath comprises detecting a peak and measuring a peak height and/or time of appearance of the peak and/or combination thereof, of a metabolic product of the isotope-labeled methacetin, the salt or the derivative of methacetin by using a breath sensor adapted to monitor the metabolic product of the isotope-labeled methacetin or the salt or the derivative thereof, in the subject's breath.
20. The method of claim 1 , wherein the evaluation of the liver function and/or the degree of injury of the liver comprises distinguishing between levels milder than cirrhosis.
21. The method of claim 20 , wherein the levels milder than cirrhosis comprise a healthy liver.
22. The method of claim 1 , wherein the analyzing comprises an Ultra-Violet (UV) absorption test.
23. The method of claim 1 , wherein the analyzing comprises a High Pressure Liquid Chromatography (HPLC) analysis.
24. A method for follow-up of a liver function and/or a degree of liver injury of a subject, comprising repeating the method of claim 1 at intervals of a predetermined period of time.
25. The method of claim 24 , wherein said predetermined period of time is between 4 hours and 12 months.